Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

abbott biologicals b.v. veerweg 12 - influenza vaccine inactivated (surface antigen)-a/brisbane/02/2018 (h1n1) pdm-like strain (a/brisbane/02/2018, ivr-190), a/kansas/14/2017 (h3n2)-like strain (a/ a/kansas/14/2017, nymc x-327), b/colorado/06/2017-like strain (b/ victoria/2/87/ lineage) (b/maryland/15/2016, nymc bx-69 a) - suspension for injection - 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose

Israel - English - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:- active immunisation of adults, including pregnant women, and children from 6 months of age and older- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women.the use of vaxigrip tetra should be based on official recommendations.

United States - English - NLM (National Library of Medicine)

novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) (unii: 5i5hvc73i8) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) - unii:euj84un96z) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. do not administer influenza a (h1n1) 2009 monovalent vaccine to anyone with a known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. [see warnings and precautions (5) and description (11) ] sanofi pasteur's influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluzone vaccine) are manufactured by the same process. available information for fluzone vaccine is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluzone vaccine. it is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e), influenza b virus (unii: 1314jz2x6w) (influenza b virus - unii:1314jz2x6w), histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3), aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), american ginseng (unii: 8w75vcv53q) (american ginseng - unii:8w75vcv53q), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinc - influenza a virus 35 [hp_x] in 1 ml - influenza   formulated for symptoms associated with colds and flu such as aches, discomfort, fatigue, respiratory dysfunction and digestive upset.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e), influenza b virus (unii: 1314jz2x6w) (influenza b virus - unii:1314jz2x6w), histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3), aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), american ginseng (unii: 8w75vcv53q) (american ginseng - unii:8w75vcv53q), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinc - influenza a virus 35 [hp_x] in 1 g - influenza   formulated for symptoms associated with colds and flu such as aches, discomfort, fatigue, respiratory dysfunction and digestive upset.

European Union - English - EMA (European Medicines Agency)

resilience biomanufacturing ireland limited - influenza vaccine (whole virion, inactivated) containing antigen of: a/vietnam/1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - influenza a virus a/california/7/2009 x-179a (h1n1) antigen (formaldehyde inactivated) (unii: xqo8062u6r) (influenza a virus a/california/7/2009 x-179a (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:c8e791ro82) - influenza a virus a/california/7/2009 x-179a (h1n1) hemagglutinin antigen (formaldehyde inactivated) 9 [hp_x] in 1 ml